XKEM aktuel empfohlen unter:
auf diese empfehlung haben schon viele ami jungs gewartet!
und der report ist nach dem ami börsenschluss herausgekommen!
1) jemand mit mir kommuniziert oder
2) wenn die aktie auf über 5 cent ist.
hat mich sehr gefreut.
gestern hab ich auch noch wie wild gepostet... naja wer nicht will...
good luck
Xechem International, Inc. (OTC BB: XKEM) Xechem International announced today that it has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA), Office of Orphan Drug Products Development, for the five-membered heterocyclic anti-sickling compound known as 5-HMF for the treatment of patients suffering from sickle cell disease (SCD).
Research led by Dr. Donald Abraham of Virginia Commonwealth University (VCU) has shown 5-HMF to be "the best potential anti-sickling agent in 30 years of sickle cell research", performed by his group. 5-HMF not only is a natural product with very little, if any, toxicity, but it has a high affinity for sickle cell hemoglobin. It is also very active in genetically modified mice as shown by Dr. Toshio Asakura, Director, and his colleagues at the NIH-NHLBI Sickle Cell Disease Reference Laboratory at the Children\'s Hospital of Philadelphia, University of Pennsylvania.
According to Xechem\'s Chairman and CEO, Dr. Ramesh Pandey, "We are pleased with the FDA\'s decision granting Orphan Drug Designation to 5-HMF. This puts Xechem into a unique position where the company will have two drugs in the pipeline for treating patients with sickle cell disease. 5-HMF is a new type of drug that interacts specifically with intracellular hemoglobin without interacting with other proteins in the body. Today there are no non-toxic drugs available on the market to treat SCD. We are actively proceeding with our first drug (NICOSAN(TM)) in the hope of bringing it to the Nigerian market immediately following Nigerian regulatory approval. We are also preparing the Investigational New Drug (IND) application for 5-HMF for submission to the FDA in the coming months."
About Orphan Drug Designation
Orphan Drug status entitles a company to various incentives including the waiver of Regulatory Filing fees, access to potential grant funding for non-clinical and clinical research to generate required data for marketing approval, and seven years of marketing exclusivity for a designated drug once approved by the FDA. (Orphan diseases are generally defined as those afflicting less than 200,000 people in the US.)
About Sickle Cell Disease
Sickle cell disease is an inherited blood disorder caused by an abnormality in the hemoglobin molecule. Patients with this disease often produce stiff, abnormally shaped red blood cells that sometimes do not flow freely through blood vessels. This can create clogs in the vessels, which in turn cuts off the flow of normal hemoglobin and oxygen to parts of the body, and can cause severe painful attacks, damage to various organs, and shortened life span. In the US, there are approximately 70-80,000 patients suffering with sickle cell disease, many of whom suffer unpredictable painful crises several times a year lasting a few hours to a week or more. In Nigeria, more than 4 million persons have the disease. Worldwide, approximately 12 million are believed to suffer from this disease.
About Xechem
Xechem International, Inc. is a development stage biopharmaceutical company whose focus and resources are currently being primarily directed toward the development and commercial launch of NICOSAN(TM) (to be marketed as HEMOXIN(TM) in the United States and Europe), which has shown efficacy in the prophylaxis management of Sickle Cell Disease (SCD). In addition to NICOSAN(TM) and 5-HMF, Xechem is also working on anticancer, antiviral (including AIDS), antifungal, antimalarial and antibacterial products from natural sources, including microbial and marine organisms. Xechem\'s mission is to bring relief to the millions of people who suffer from these diseases. Its focus is on the development of phyto-pharmaceuticals (Natural Herbal Drugs) and other proprietary technologies, including those used in the treatment of orphan diseases.
Forward Looking Statements
This press release contains certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward looking statements involve known and unknown risks and uncertainties.
Xechem International, Inc.
Stephen Burg, 707-426-8855
Source: Business Wire (June 6, 2006 - 6:30 AM EDT)
News by QuoteMedia
www.quotemedia.com
The SouthEnd Stock Pickers helps investors win at investing on the merits of radically original thinking and an unbeatable track record of picking stocks with huge potential. We're here for you with commonsense,the big ideas,and little inspiration to turn your portfolio into a monster performer.We've brought you GTE,GOOG,SIRI,PTSC,JDSU,HISC,and others you've made a killing on! If it doesn't
make commonsense,it makes no sense to us or you.
Bookmark this page NOW for update picks!
AT SouthEndStockPickers, we're focusing solely on undervalued Nasdaq stocks that we feel will return potential profits of 500%+ in 1 to 3 weeks.
We feel this stock pick is very UNDERVALUED!
This Company is a SLEEPING GIANT ready to be AWOKEN.
SouthEndStockpickers Pick of the month is (XKEM).
Text zur Anzeige gekürzt. Gesamtes Posting anzeigen...
We can not believe how UnderValued (XKEM) is.It should be tradeing at $0.12 to $0.18 right now with current news.But we don't mind we are doing some major Accumulation at current price levels.SouthEndStockPickers are going long term on this hidden GEM.
If you recall (PTSC) that went from $0.12 to $2.50 less then 2 months.It's XKEM turn but BIGGER Potential. Shareholders of (XKEM) haven't seen anything yet this is just the Start of a Biotechnology company in the making thats growing bigger minute by minute.Competitors like Bristol-Myers Squibb ,Genentech Inc,and many more will keep a very close eye on Xechem International Inc,
Stock Alert! = Xechem International Inc.
Ticker Symbol = XKEM
Sector:Healthcare
Industry: Biotechnology
Website = www.xechem.com
Short Term Target Price = $1.35
Long Term Target Price = $7.00
Disclosure = We Own Shares
Recommendation = MEGA BONUS BUY !!!
Information To Consider
1.Xechem International, Inc. announced today that its Nigerian subsidiary, Xechem Pharmaceuticals Nigeria Ltd. (Xechem Nigeria), has successfully closed on a N150 Million Naira ($1.2 million) loan from the Nigerian Export-Import (NEXIM) Bank. The loan has a three year term, with a moratorium on repayment of principal during the first year. Xechem International is neither a borrower nor a guarantor under the loan facility in this transaction.
As previously reported by Xechem International, Xechem Nigeria has submitted its Drug Master File (DMF) dossier with Nigeria's drug regulatory agency, the National Agency for Food and Drug Administration and Control (NAFDAC), seeking full registration for NICOSAN(TM). It is currently awaiting final word from that agency on its submission. Subject to the necessary approvals, Xechem has indicated that it would like to launch the drug in Nigeria by early July 2006, and shortly thereafter to embark on the clinical trials in the US hospitals for FDA approval through the Investigational New Drug (IND) Application for sale of the drug in the United States.
2.Obasanjo to launch locally produced sickle cell drug.President Olusegun Obasanjo will by June launch NIPRISAN (HEMOXIN(TM)), the locally produced drug for sickle cell disorder.The president will also use the occasion to commission Xechem International Inc. factory in the country in a move seen as a landmark investment in Nigeria. The company owns the exclusive rights to NIPRISAN.
3.Xechem Files Orphan Drug Application with the FDA For The Anti-Sickling Compound Licensed From Virginia Commonwealth University.
4.Xechem Closes On $4.2 Million Lawsuit Settlement With Bristol-Meyers Squibb.
5.Xechem International, Inc. is a development stage biopharmaceutical company focusing on anticancer, antiviral (including AIDS), antifungal, Sickle Cell Disease (SCD), antimalarial and antibacterial products from natural sources, including microbial and marine organisms as well as the development of phyto-pharmaceuticals and other proprietary technologies, including those used in the treatment of orphan diseases. Xechem's mission is to bring relief to the millions of people who suffer from these diseases. Its primary attention and resources are currently being directed toward the development and commercial launch of the phyto-pharmaceutical NICOSAN(TM)/HEMOXIN(TM), which has shown efficacy in the treatment of SCD.
REUTERS gives XKEM a "LOW - RISK ALERT"
Alert Two Institutions holding (XKEM) shares now. And we just got word that a third Institution is doing some Major Accumulation.
fein, dass du dich entschieden hast meine fred zu bereichern!
hab mir die letzten tage ja die finger wund geschrieben um alle hier im board auf die chance aufmerksam zu machen! langsam dürfte es was bringen...
intercell: die stehen ebenso wie XKEM kurz vor der markteinführung eines neuen ersten medikaments, sie haben ebenfalls den orphan drug status bekommen, somit sind sie sie durchaus vergleichbar.
unterschied?
INTERCELL MK: fast 500 millionen euro
XKEM MK: cirka 25 millionen dollar
und ich halte intercell noch für unterbewertet (sonst waer ich ja nicht investiert)
also wer ein bisschen kleingeld über hat sollte sich diesen zock überlegen - das einzige was natürlich zu bedenken ist, ist dass die otc sicherlich ein heisseres pflaster als die wiener börse ist, aber das muss ich hier ja wohl niemendem erzählen.
Gesundheits-Lexikon
Sichelzellenkrankheit (Sichelzellenanämie):
Erbkrankheit, bei der fehlerhafter roter Blutfarbstoff gebildet wird und dadurch die Überlebenszeit der roten Blutkörperchen verkürzt ist. Es entsteht eine Blutarmut (Anämie) durch chronischen Zerfall von roten Blutkörperchen (Hämolyse).
Ursache:
Ein rezessiv erblicher Defekt bewirkt den Austausch eines Eiweißbausteines im roten Blutfarbstoff, was zur Folge hat, dass bei Sauerstoffmangel die roten Blutkörperchen Sichelform annehmen. Die S. ist bei Afrikanern und Afroamerikanern häufig, kommt aber auch in Südeuropa vor. Bei den heterozygoten Merkmalsträgern ist noch ein intakter Genabschnitt vorhanden, das Krankheitsbild ist bei ihnen nur geringgradig ausgeprägt. Auffällig ist eine relative Resistenz gegen Malaria. Bei homozygoten Merkmalsträgern (mit Schädigung beider Genabschnitte) ist nahezu der gesamte Blutfarbstoff geschädigt und die Erkrankung voll ausgebildet.
Befund:
Auslösende Situationen für eine Sichelzellkrise sind v. a. Aufenthalte in kalter Umgebung oder großer Höhe, körperliche Überanstrengung und Krankheit. Die Sichelzellen führen zu schweren Schmerzkrisen insbesondere im Bauch, in Knochen und Gelenken. Gleichzeitig bestehen oft Schwellungen von Händen und Füßen. Durch Verstopfen von Kapillaren (Haargefäße) können die Sichelzellen zu Organschädigungen führen: Betroffen ist sehr häufig die Milz, jedoch auch die Netzhaut des Auges sowie Hirn, Nieren und Knochen. Weitere häufige Probleme sind bei Männern Impotenz, bei Frauen wiederholte Fehlgeburten. Bei Blutuntersuchungen wird eine chronische Anämie mit unterschiedlich großen roten Blutkörperchen (Anisozytose) nachgewiesen, die z. T. sichelförmig aussehen können.
Behandlung:
Eine Therapie ist nur während der Krise notwendig, sie erfolgt dann mit Sauerstoff, starken Schmerzmitteln, reichlicher Flüssigkeitszufuhr und Antibiotika. Situationen, die zu einer Sichelzellkrise führen können (siehe oben), sollten möglichst vermieden werden.